COMMUNIQUÉS West-GlobeNewswire

Cytokinetics Announces Pricing of Upsized Public Offering of Common Stock
07/05/2026
SOUTH SAN FRANCISCO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the pricing of an underwritten public offering of 9,859,155 shares of its common stock at a price [...]
InnoCare Announces Approval of Clinical Trial of Novel CDH7 targeted ADC ICP-B208 in China
07/05/2026
BEIJING, May 06, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Center for [...]
SteelPower Male Enhancement Ingredient Research Gains Attention Amongst Men for Powerful Performance Support
07/05/2026
SteelPower Male Enhancement Scam Searches, Complaints, Ingredients, Refund Policy, and Pricing Explained for 2026 Aurora, CO, May 06, 2026 (GLOBE NEWSWIRE) -- These statements have not been evaluated by the Food and [...]
SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
07/05/2026
JERSEY CITY, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX) (“SCYNEXIS” or the “Company”), a biotechnology company focused on developing innovative new therapies to address severe rare diseases [...]
Memora Claims Evaluated: New Memory Health Report Examines Advanced Brain Health Supplement for Preventing Cognitive Decline
07/05/2026
How Bacopa Monnieri, Lion's Mane, Ginkgo Biloba, Rhodiola Rosea, and Panax Ginseng Support Memory Function and Cognitive Wellness in 2026 Tallmadge, OH, May 06, 2026 (GLOBE NEWSWIRE) -- These statements have not been [...]
TOMI Environmental Solutions, Inc. to Hold Conference Call to Discuss First Quarter 2026 Financial Results on May 8, 2026
07/05/2026
FREDERICK, Md., May 06, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today announced it will report [...]
Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer
07/05/2026
Data contributed to the scientific and clinical rationale for RASolute 302, a pivotal Phase 3 trial in second line treatment of patients with metastatic pancreatic cancer REDWOOD CITY, Calif., May 06, 2026 (GLOBE [...]
Totus Medicines Presents Early Phase 1b Clinical Data Demonstrating 100% Disease Control Rate and Class-Leading Safety for TOS-358 + Fulvestrant Doublet Therapy in HR+/HER2- Breast Cancer at ESMO Breast Cancer Annual Congress 2026
07/05/2026
TOS-358 is a covalent, pan-mutant, a -selective PI3K inhibitor designed to address key limitations of existing PI3K a therapies which include limited mutation coverage and poor tolerability First presentation of [...]
InsuLeaf Claims Evaluated: The Safer & More Effective than GLP-1 Drugs, Natural Leak Peak Formula
07/05/2026
How InsuLeaf's Chromium, Alpha Lipoic Acid, Cinnamon, Gymnema sylvestre, and Bitter Melon Blood Sugar Support Formula Compares to GLP-1 Drug Searches in 2026 Largo, FL, May 06, 2026 (GLOBE NEWSWIRE) -- The phrase "safer [...]
Precision Optics Schedules Third Quarter of Fiscal Year 2026 Conference Call for May 13, 2026
06/05/2026
LITTLETON, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (Nasdaq: POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/ [...]
Rapid Micro Biosystems to Announce First Quarter 2026 Financial Results on May 13, 2026
06/05/2026
LEXINGTON, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to [...]
Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements
06/05/2026
Generated first quarter XDEMVY ® net product sales of more than $145 million, an increase of more than 85% year-over-year Reaffirmed full-year 2026 guidance of $670-700 million of XDEMVY net product sales and peak sales [...]
Context Therapeutics Reports First Quarter 2026 Operating and Financial Results
06/05/2026
Phase 1a interim data for ongoing CTIM-76 (CLDN6 x CD3) trial expected in June 2026 Phase 1a interim data for ongoing CT-95 (MSLN x CD3) trial expected in September 2026 Phase 1 initiation for CT-202 (Nectin-4 x CD3) [...]
Tenaya Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
06/05/2026
One-Year Cohort 1 Data and Initial Cohort 2 Data from RIDGE™-1 Phase 1b/2 Trial of TN-401 for PKP2-Associated ARVC to be Presented at ASGCT 2026 New Data from Both Cohorts of the MyPEAK™-1 Phase 1b/2 Trial of TN-201 for [...]
RxSight, Inc. Reports First Quarter 2026 Results and Reiterates Full-Year Sales Outlook
06/05/2026
ALISO VIEJO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today reported financial results for the quarter ended March 31, 2026. Strategic Highlights and Recent Developments Q1 sales of $30.9 [...]
Sight Sciences Reports First Quarter 2026 Financial Results and Raises Full Year 2026 Revenue Guidance
06/05/2026
MENLO PARK, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, [...]
iMDx to Release First Quarter 2026 Results on May 13, 2026
06/05/2026
NASHVILLE, Tenn., May 06, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that it will report first quarter 2026 financial results after the market closes on [...]
BiomX’s Zorronet Puts Full AI Command-and-Control in the Palm of Your Hand
06/05/2026
Transforms fragmented communication into real-time, AI-driven coordination, assignment, and guided response NETANYA, Israel, May 06, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE: PHGE) (“BiomX” or the “Company”) today [...]
ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update
06/05/2026
1Q 2026 Total Revenue of $114.5 Million, Flat Year-Over-Year 1Q 2026 ASCENIV Revenue +28% Year-Over-Year; BIVIGAM Revenue -54% Year-Over-Year 1Q 2026 Adjusted Net Income ( 1) of $40.7 Million, 22% Year-Over-Year Growth [...]

Pages